Latest News about fda
Recent news which mentions fda
Psychedelics Researchers & Industry Leaders Weigh In On Groundbreaking PTSD Treatment News
September 15, 2023
Tickers
NUMIF
From Benzinga
Personalized Skin Cancer Therapy, Despite FDA Delay: Analysts Show Confidence In Iovance Biotherapeutics Therapy
September 15, 2023
Tickers
IOVA
From Benzinga
Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next
September 14, 2023
From Benzinga
Despite FDA Doubts, Adcomm Backs Alnylam's Gene Silencing Therapy For Expanded Use Into Rare Heart Disease
September 14, 2023
From Benzinga
Medication Shortage For ADHD: Urgent FDA/DEA Action Needed, Is Cannabis An Alternative?
September 13, 2023
Tickers
DEA
From Benzinga
FDA Panel Says Popular OTC Cold, Allergy Medicine Might Be Useless - Stocks To Watch
September 12, 2023
From Benzinga
CVS, Walgreens Boots Among Firms Receiving Warning Letter Against Selling Unapproved Eye Products
September 12, 2023
From Benzinga
Moderna, Pfizer Get FDA Nod For Omicron COVID Boosters While Novavax Waits
September 11, 2023
From Benzinga
Shaping Federal Policy Around Psychedelic Therapy: APPA Teams Up With Daschle Group
September 07, 2023
From Benzinga
Report: 650% Spike In Cannabis Medicine Trials Prioritizing Chronic And Neuropathic Pain
September 06, 2023
From Benzinga
PharmaTher Aims To Mitigate Ketamine Shortage With New FDA Application
September 06, 2023
Tickers
PHRRF
From Benzinga
From Benzinga
Governor Jared Polis Addresses President Biden On Cannabis Rescheduling: What It Means For States Like Colorado
September 06, 2023
Tickers
DEA
From Benzinga
FDA Seeks Further Safeguards for AstraZeneca's Ultomiris Therapy, But Efficacy Not in Question
September 06, 2023
Tickers
AZN
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.